BiotechTube

duloxetine + duloxetine

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Major Depression

Conditions

Major Depression

Trial Timeline

Sep 1, 2005 → Mar 1, 2009

NCT ID
NCT00149110

About duloxetine + duloxetine

duloxetine + duloxetine is a pre-clinical stage product being developed by Eli Lilly for Major Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00149110. Target conditions include Major Depression.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT00149110Pre-clinicalCompleted

Competing Products

20 competing products in Major Depression

See all competitors
ProductCompanyStageHype Score
Duloxetine HydrochlorideEli LillyPre-clinical
23
LY2216684Eli LillyPhase 1
33
LY2216684Eli LillyPhase 1
33
DuloxetineEli LillyPhase 3
77
LY2216684 + DigoxinEli LillyPhase 1
33
Duloxetine + ParoxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
52
FK949EAstellas PharmaPhase 1
33
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
52
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
Mirtazapine TabletsSun PharmaceuticalApproved
85
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Pramipexole ER + EscitalopramCiplaPhase 2
52
LY2216684 + SertralineEli LillyPhase 1
33
LY2216684 + Placebo + LorazepamEli LillyPhase 1
33
LY2216684 + SSRIEli LillyPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85